Skip to Content

A promising schizophrenia drug showed mixed results. What does that mean for patients?

AP Medical Writer

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the research. That’s according to company-sponsored studies reported Thursday. Schizophrenia is a severe mental illness that can cause people to hear voices, feel paranoid and withdraw from others. Bristol Myers Squibb’s Cobenfy was approved by the U.S. Food and Drug Administration in September. There’s been great hope among doctors because the drug acts in the brain differently than other schizophrenia medicines. The latest results presented at a medical meeting in Boston come from two yearlong studies.

Article Topic Follows: AP National News

Jump to comments ↓

Associated Press

BE PART OF THE CONVERSATION

News Channel 3 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content